Influenza A virus H7N9 vaccine - EpiVax

Drug Profile

Influenza A virus H7N9 vaccine - EpiVax

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiVax
  • Developer EpiVax; Flinders University; Vaxine
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 18 Sep 2017 Epivax, the University of Massachusetts Medical School, Protein Sciences Corporation and the University of Georgia agree to co-develop influenza A H7N9 vaccine for Influenza-A virus H7N9 subtype
  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
  • 18 Sep 2016 Phase-I clinical trials in Influenza-A virus H7N9 subtype in USA (Parenteral) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top